Background

The Scottish Burden of Disease (SBoD) study team have published comprehensive estimates of the burden of disease and injury in Scotland for 2016 [1]. The purpose of this technical overview is to provide background information on the data and methodology used, noting any caveats associated with estimating the burden of breast cancer in SBoD.

Burden of disease studies aim to estimate the difference between ideal and actual health in a country or region at a specific point in time. Individuals can suffer non-fatal health loss due to suffering disability attributable to a disease, or injury, or suffer fatal health loss which is early death due to a disease or injury. To quantify the total burden, non-fatal and fatal health loss are combined to produce a single metric called the Disability-Adjusted Life Year (DALY).

In SBoD 2016, all data are presented as three year averages for period 2014-2016. A three year period is used to smooth out most of the effect if the mortality or morbidity of a single year happens to be unusual. Further information about the SBoD study, including a more thorough explanation of the methodology used, overview reports, detailed results and other specific disease briefings, can be found on the website of the Scottish Public Health Observatory (ScotPHO) [1].

Estimated burden due to breast cancer

Breast cancer was the 17th most common cause of disease burden in Scotland in 2016, resulting in a total of approximately 19,800 DALYs. Of this total burden, 88% was due to premature mortality attributed to breast cancer and 12% was attributed to the health loss suffered due to living with breast cancer.

Overall, 45% of the total breast cancer burden was contributed by women aged 45 to 64 years, with women aged 65yrs and over contributing 41% to the total cancer burden, as outlined in Figure 1. Men contributed 0.3% of the total burden of breast cancer. Note that the burden we are describing is the absolute burden and has not been adjusted for the age/gender case-mix.
The age standardised DALY rates for breast cancer, by deprivation¹ decile, are shown in Figure 2. The highest DALY rates 2,089 per 100,100 were found in the most deprived area (decile 1) but these were only slightly higher than those found in the 10% least deprived area in Scotland, 1,923 per 100,000). Similarly, premature mortality accounts for 77% of total burden in the most deprived area compared to 73% in least deprived area.

Figure 2 Breast cancer DALY (rates per 100,000²) by deprivation decile

We used the Scottish Index of Multiple Deprivation (SIMD 2016) to analyse patterns of inequality in the burden of disease across Scotland. SIMD2016 is categorised into deciles 1 (most deprived) to 10 (least deprived), SIMD2016 calculates deprived areas, not deprived individuals.

Where the data were age-standardised, this was done directly using the 2013 European Standard Population to account for differences in age structure between SIMD deciles.

---

¹ We used the Scottish Index of Multiple Deprivation (SIMD 2016) to analyse patterns of inequality in the burden of disease across Scotland. SIMD2016 is categorised into deciles 1 (most deprived) to 10 (least deprived), SIMD2016 calculates deprived areas, not deprived individuals.

² Where the data were age-standardised, this was done directly using the 2013 European Standard Population to account for differences in age structure between SIMD deciles.
How did we produce these estimates?

DALYs attributed to a disease, or injury, are calculated by combining estimates from two individual metrics: Years of Life Lost (YLL) due to premature mortality and Years Lived with Disability (YLD).

Years of Life Lost (YLL) due to breast cancer

YLL measures the years of life lost due to premature deaths i.e. the fatal component of burden of disease. YLLs are calculated by subtracting the age at each breast cancer death from the expected remaining life expectancy for a person at that age.

Estimating the number of deaths

For the period 2014-2016, we estimated an average of 1,073 deaths per year caused by breast cancer. These deaths were identified from the underlying cause of death on the National Records of Scotland (NRS) register of deaths [2] and the Global Burden of Disease 2016 cause list, which has been classified using the International Statistical Classification of Diseases and Related Health Problems (ICD) [3,4]. The NRS register of deaths has a Community Health Index (CHI) number attached to each death, which allows for demographic data such as gender, geographical area of residence and age at death to be established for each individual.

Included in the total breast cancer mortality count are deaths that have come from what are termed ill-defined death groups in burden of disease studies. In SBoD, these ill-defined deaths are redistributed amongst specific causes of death across the burden of disease cause list based on the secondary causes of death recorded on the death certificate. For a small number of cases, where there was no additional information relating to secondary causes of death, the individuals clinical history was evaluated to inform the target cause for redistribution. For breast cancer, approximately 4% of the mortality count comes from these ill-defined deaths. For this reason, the number of deaths due to breast cancer which have been reported are different from that of officially reported sources. Further explanation of this method is available in the Invited chapter of The Registrar General’s Annual Review of Demographic Trends [5].

Years of life lost (YLL) due breast cancer

Each single death contributes to the total YLL through calculating the difference between the age at death and the life expectancy at that age. Life expectancy was defined using the 2014-2016 gender-specific National Life Tables for Scotland [6]. There were approximately 17,500 YLL due to breast cancer in Scotland in 2016. Dividing the total YLL for breast cancer by the total number of deaths indicates that, on average, women who die due to breast cancer die 16 years younger than would be otherwise expected on the basis of the life expectancy of the general population.
Years Lived with Disability (YLD) due to breast cancer

Years lived with disability (YLD) are estimated using:

- disease and injury prevalence estimates
- levels of severity
- disability weights

Our sources of information for these three components were as follows:

**Estimating the number of individuals suffering disability**

To estimate prevalent cases of breast cancer in 2016, we used individual level data from the Scottish Cancer Registry and linked it to the NRS Register of Deaths using the Community Health Index (CHI). The linkage of datasets allowed us to identify individuals that were still living at 31 December 2016 and had a recorded date of incidence with a diagnosis of breast cancer between 2006 and 2015. This time period was chosen to match the specifications of the GBD 2016 study [7]. The list of ICD-10 codes that were used to define mortality due to breast cancer was also used to identify prevalent cases of breast cancer.

Using this method of identifying prevalent cases, we estimated that there were approximately 49,200 individuals in the Scottish population suffering disability due to breast cancer in 2016.

**Severity distribution and disability weights**

The levels of severity and disability due to breast cancer in Scotland were based on the specifications of the GBD 2016 study [7]. This study allocates cases of breast cancer into four different severity levels: diagnosis and primary therapy, controlled phase, metastatic phase and terminal phase.

The transition from one severity level to another is linked to specific clinical events and mortality outcomes of an individual after their initial incident diagnosis of breast cancer. The amount of days that a breast cancer prevalent case would remain in the diagnosis and primary therapy phase and the metastatic phase is based on average durations used in the GBD 2015 study (see Figure 2). GBD 2015 defines the severity levels as follows:

“Diagnosis and primary therapy are defined as the time from symptoms onset to end of treatment. Controlled phase is defined as the time after finishing primary treatment and either cure (defined as survival after 10 years) or metastatic phase. Metastatic phase is defined as the time period of intensive treatment for metastatic disease; terminal phase is defined as the one month period prior to death.”
Figure 2 Transition from one severity level to another for a cancer case. Individuals dying before ten years after diagnosis will go through all the cancer stages and, except for the controlled stage, remain in it for a fixed period of time. The duration at each stage is based on the results from GBD 2015 study [7]

![Transition Diagram](image)

The disability weights were developed by the GBD study through surveys of the general public and take into account the consequences of each disease and injury [8]. The severity distribution and disability weights for breast cancer, as well as the YLD for each severity level are outlined in Table 1. In addition, we also consider the burden associated with the long-life consequences of a mastectomy, for those individuals that survive longer than ten years and underwent this procedure as part of the cancer treatment.

Once the disability weight of each severity level was taken into account, individuals were estimated to be suffering approximately 5,800YLD in 2016 due to living with breast cancer.

Table 1 Severity levels, description and disability weights associated with breast cancer in 2015.

<table>
<thead>
<tr>
<th>Severity level</th>
<th>Description</th>
<th>Individuals</th>
<th>Disability weight</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis and primary therapy</td>
<td>Has pain, nausea, fatigue, weight loss and high anxiety.</td>
<td>683</td>
<td>0.288</td>
</tr>
<tr>
<td>Controlled phase</td>
<td>Has a chronic disease that requires medication every day and causes some worry but minimal interference with daily activities.</td>
<td>46,796</td>
<td>0.049</td>
</tr>
<tr>
<td>Metastatic phase</td>
<td>Has severe pain, extreme fatigue, weight loss and high anxiety.</td>
<td>1,583</td>
<td>0.451</td>
</tr>
<tr>
<td>Terminal phase</td>
<td>Has lost a lot of weight and regularly uses strong medication to avoid constant pain. The person has no appetite, feels nauseous, and needs to spend most of the day in bed.</td>
<td>102</td>
<td>0.54</td>
</tr>
</tbody>
</table>
Data quality

In order to provide a measure of the degree of accuracy\(^3\) and relevance\(^4\) of the estimated disease DALYs to users, a measure of data quality has been developed for the SBoD study. This measure assigns a RAG (Red; Amber; Green) status to each disease or injury indicative of the accuracy and relevance of the estimates. Interpretation of the RAG status can be defined as follows:

**RAG Highly accurate and relevant**
Estimates have been derived using relevant and robust data sources with only a small degree of adjustments performed to the input data.

**RAG Moderately accurate and relevant**
Estimates have been derived using reasonably relevant and robust data sources with only a moderate degree of adjustments performed to the input data.

**RAG Uncertainties over accuracy and relevance**
Estimates have been derived using less comprehensive or relevant data sources with a high degree of adjustments performed to the input data.

The data quality has been assessed using three main criteria:

- Relevance and accuracy of the data source used to measuring the population of interest
- Likelihood that the implemented disease model captured the overall burden of disease or injury
- The relative contribution of ill-defined deaths to YLL, and YLL to DALY.

These criteria are subjectively assessed and each criterion is scored on a scale of 1 to 5. Further details on these data quality measures are available on the ScotPHO website [1].

Based on these criteria, the estimates of burden of breast cancer in Scotland are green, **RAG highly accurate and relevant**.

When estimating the burden of breast cancer, we have estimated that 88% of the burden is attributed to premature mortality due to breast cancer. Scottish mortality data is deemed to be of high-quality, which is the main reason for this assessment [2]. Our study estimated a breast cancer prevalence of approximately 49,200 in Scotland in 2016, similar to that based on prevalence estimates in the publication Cancer in Scotland [9]. In comparison, the Global Burden of Disease study (GBD) 2016 estimated a lower breast cancer prevalence of 22,230 [10].

---

\(^{3}\) How precise, unbiased or certain the estimate is.

\(^{4}\) Do we measure the thing we want to measure?
What next to improve estimates for breast cancer

Future work on the SBoD study will attempt to refine the definition of the transitions from one severity level to another. This work will use more detailed information from the Cancer Registry [9] to determine the amount of time an individual spends in each of the four phases and take into account diseases stage at diagnosis, instead of relying on average durations. For instance, prevalent cases detected very early (for instance, through a cancer screening program) may have a different disease and disability trajectory from other cancers.

These improvements are partly dependant on exploring other data sources and reviewing evidence from high quality research that it is relevant to Scotland. Please contact the SBoD project team (nhs.healthscotland-sbod-team@nhs.net) for enquiries and suggestions on how to improve our estimates.
References


